Applied DNA Sciences Collaborates with Stony Brook University
News Mar 22, 2006
Dr. Sanford Simon, Professor of Biochemistry, Cell Biology, and Pathology, Stony Brook University, and a director of APDN, will lead this project entitled "A Chimeric Method and System for DNA Encryption and Authentication" on behalf of the University together with Dr. Benjamin Liang, Strategic Technology Officer for Applied DNA Sciences.
Stony Brook University's Center for Advanced Technology in Biotechnology has made a grant of $79,005.77 to APDN to partially fund the project.
"We are very pleased to facilitate what we hope will be the first of many collaborative projects between the University and Applied DNA Sciences," stated Dr. Clinton T. Rubin, Director, Center for Biotechnology and Professor and Chair, Department of Biomedical Engineering, Stony Brook University.
"The Center will work closely with APDN to facilitate access to both the University's and the region's life sciences infrastructure to help fuel the company's growth on Long Island."
Dr. James A. Hayward, CEO of APDN, stated, "This is an important collaboration for APDN because it may help us find a more direct path to commercialization. We believe our DNA encryption and authentication system will add tremendous value to the prevention of counterfeiting and piracy."
"Our technology could also complement existing security solutions like holograms, inks, threads and labels."
"We believe our technology will greatly enhance the capabilities of product origination, identification, verification and validation of the source of components for critical manufacturing, defense, medical and other high-integrity products."
Dr. Sanford Simon, Professor of Biochemistry, Cell Biology and Pathology, Stony Brook University, said, "I am pleased to provide additional technical resources and support towards this project."
"Together with Dr. Liang, and APDN, we will be developing an inventory of chimeric DNA and developing authentication systems which will be incorporated into a range of different commercial and government applications."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.